Valuation: Berkley Renewables Inc.

Market Cap 4L 3L 3L 3L 5L 3.5Cr 5L 36.57L 14.17L 1.79Cr 13.68L 13.38L 5.75Cr P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 51.26L 45.54L 42.5L 38.74L 73.07L 49Cr 73.75L 5.14Cr 1.99Cr 25Cr 1.92Cr 1.88Cr 81Cr EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
Manager TitleAgeSince
Chief Executive Officer 63 20/06/2002
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 17/08/2006
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5L
-0.24%-0.43%+35.74%+8.24% 15TCr
+1.53%+2.87%+57.33%+60.16% 9.99TCr
+0.05%+0.73%+28.06%+14.33% 7.42TCr
-0.30%-0.90%-7.04%-5.17% 6.89TCr
+2.78%+5.59%+98.16%+68.30% 5.98TCr
+0.41%+2.15%+31.31%-6.77% 5.81TCr
+1.04%+1.28%+38.84%+4.38% 5.48TCr
-0.43%-1.05%+29.00%+22.98% 5.17TCr
+1.13%-1.51%+35.77%-13.82% 4.13TCr
Average +0.60%+0.14%+38.57%+16.96% 6.61TCr
Weighted average by Cap. +0.56%+0.33%+38.67%+18.95%

Financials

2016 2017
Net sales 10.34L 9L 9L 8L 14.74L 9.94Cr 14.88L 1.04Cr 40.21L 5.08Cr 38.82L 37.98L 16Cr 17.25L 15.32L 14.3L 13.04L 24.59L 17Cr 24.82L 1.73Cr 67.07L 8.48Cr 64.76L 63.35L 27Cr
Net income 2L 2L 1L 1L 2L 1.66Cr 2L 17.33L 7L 84.87L 6L 6L 2.72Cr -6L -6L -5L -5L -9L -6.06Cr -9L -63.28L -24.52L -3.1Cr -23.67L -23.16L -9.94Cr
Net Debt 29.17L 25.92L 24.19L 22.05L 41.58L 28Cr 41.97L 2.93Cr 1.13Cr 14Cr 1.1Cr 1.07Cr 46Cr 47.61L 42.3L 39.48L 35.99L 67.87L 46Cr 68.5L 4.78Cr 1.85Cr 23Cr 1.79Cr 1.75Cr 75Cr
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-